Table 1_Immunotherapy-based adjuvant treatment after neoadjuvant immunochemotherapy in eso

A retrospective analysis of 260 patients with locally advanced esophageal squamous cell carcinoma who underwent radical resection after neoadjuvant immunochemotherapy between 2019 and 2023. The dataset compares disease-free and overall survival outcomes for patients receiving immunotherapy-based adjuvant treatment versus observation, stratified by pathological response status. The study was authored by Chenyu Wang and shared under a CC-BY-4.0 license.

Use Cases

• Compare survival outcomes (DFS/OS) between adjuvant treatment and observation based on pathological response status.
• Analyze the potential benefit of adjuvant immunotherapy in the subgroup of non-pCR patients with pathological downstaging.
• Evaluate the comparative efficacy of adjuvant immunotherapy alone versus adjuvant immunochemotherapy using the reported survival rates.

Strengths

• Contains data from 260 patient records with a median follow-up of 36.8 months.
• Analyses were adjusted for baseline imbalances using propensity score matching and inverse probability of treatment weighting.
• Includes specific 3-year survival rates for key patient cohorts, such as a 90.1% 3-year DFS for pCR patients under observation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying patient-level data is unknown, which may limit suitability assessment.
• The data is contained in a 17.6 MB DOCX file, which may require extraction to access structured data.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patient medical records.

Time Range

2019 to 2023

Freshness

Last updated 2026-06-03 06:04:42; freshness should be verified.